4//SEC Filing
Vavricka John 4
Accession 0000899243-20-030323
CIK 0001593899other
Filed
Nov 2, 7:00 PM ET
Accepted
Nov 3, 8:04 PM ET
Size
7.4 KB
Accession
0000899243-20-030323
Insider Transaction Report
Form 4
Vavricka John
Chief Commercial Officer
Transactions
- Conversion
Common Stock
2020-11-03+82,508→ 82,508 total(indirect: By Trust) - Conversion
Series B Convertible Preferred Stock
2020-11-03−82,508→ 0 total(indirect: By Trust)→ Common Stock (82,508 underlying)
Footnotes (1)
- [F1]The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.
Documents
Issuer
Atea Pharmaceuticals, Inc.
CIK 0001593899
Entity typeother
Related Parties
1- filerCIK 0001829630
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 7:00 PM ET
- Accepted
- Nov 3, 8:04 PM ET
- Size
- 7.4 KB